Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate C4 Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding C4 Therapeutics, Inc.’s stock price such as:

• C4 Therapeutics, Inc.’s current stock price and volume
• Why C4 Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for CCCC from analysts
• CCCC’s stock price momentum as measured by its relative strength

About C4 Therapeutics, Inc. (CCCC)

Before we jump into C4 Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Want to learn more about C4 Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about C4 Therapeutics, Inc..

C4 Therapeutics, Inc.’s Stock Price as of Market Close

As of February 19, 2026, 4:00 PM, CST, C4 Therapeutics, Inc.’s stock price was $2.120.

C4 Therapeutics, Inc. is up 10.99% from its previous closing price of $1.910.

During the last market session, C4 Therapeutics, Inc.’s stock traded between $1.875 and $2.120. Currently, there are approximately 72.56 million shares outstanding for C4 Therapeutics, Inc..

C4 Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

C4 Therapeutics, Inc. Stock Price History

C4 Therapeutics, Inc.’s (CCCC) price is currently up 11.58% so far this month.

During the month of February, C4 Therapeutics, Inc.’s stock price has reached a high of $2.120 and a low of $1.690.

Over the last year, C4 Therapeutics, Inc. has hit prices as high as $3.650 and as low as $1.085. Year to date, C4 Therapeutics, Inc.’s stock is up 10.99%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused C4 Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 19, 2026, there was 1 analyst who downgraded C4 Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate C4 Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on C4 Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

C4 Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about C4 Therapeutics, Inc. (CCCC) by visiting AAII Stock Evaluator.

Relative Price Strength of C4 Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 19, 2026, C4 Therapeutics, Inc. has a weighted four-quarter relative price strength of -5.77%, which translates to a Momentum Score of 30 and is considered to be Weak.

Want to learn more about how C4 Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

C4 Therapeutics, Inc. Stock Price: Bottom Line

As of February 19, 2026, C4 Therapeutics, Inc.’s stock price is $2.120, which is up 10.99% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like C4 Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.